Pricing Log in Create free account
Friday 6 November 2026 Export SMTI’s income statement to Excel — free account

Sanara MedTech Inc.

SMTI Healthcare Medical Instruments & Supplies

Sanara MedTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $103.1 million, up 19.0% from fiscal 2024.

Revenue
+9.04%
EPS
+78.3%
Free cash flow
+131.3%
Total debt
+5.11%

Quarter to June 2026, against a year earlier

31.70 0.09 +0.28%
Market cap
$290.4M
P/E
0.0×
Fwd P/E
164×
Dividend yield
—
F-score
4/9
Altman Z
2.35
Beneish M
−3.22
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 43.67%

Capital & Financial Ratios $m

Size
Market Cap 290.43
Revenue ttm 109.81
Net income ttm (32.02)
Free cash flow ttm 4.50
Net debt Q 31.06
Valuation
P/E 0.00
Forward P/E 164.00 (above 35: high)
Price / sales 2.50
Forward P/S Powerpack
Price / FCF 61.58
Price / book 34.59 (above 6: high)
Financial health
Current ratio Q 2.58 (at or above 1.5: strong)
Debt / equity Q 5.86 (above 2: weak)
Interest coverage Q 0.98
Growth
Revenue growth Q +9.04% (above 0%: growing)
Operating income growth Q −28.42% (below 0%: shrinking)
EPS, this year +480.00% (at or above 15%: strong)
EPS, next year A +207.89% (at or above 15%: strong)
Revenue, next year A +13.07% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −8.82% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 3.2×; over the ten years it ranged from 0.3× in 2019 to 18.4× in 2020.
P/S against its own 10 years 40.26%
10-year low 10-year high
P/B against its own 10 years 90.21%
10-year low 10-year high
EV/Sales against its own 10 years 41.11%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 5 16 17 15
Receivables 9 12 12 13
Inventory 5 3 4 3
Other — — — —
19 33 34 32
2023 2024 2025 Q'26
Payables 2 2 2 1
ST’ Debt 1 — — —
Other 1 — 0 —
14 15 19 12

Compound Annual Growth %

10y 5y 3y
Sales 40.78% 45.92% 31.02%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.30% (47.81%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.02 Actual 0.05

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.24 0.09 Beat by 0.33
Q4 FY25 0.11 0.04 Miss by 0.07
Q1 FY26 −0.04 0.04 Beat by 0.08
Q2 FY26 0.02 0.05 Beat by 0.03
Q3 FY26 0.06 — Reports 11 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.05 (0.05) — — —
’25 (0.41) (0.23) (3.40) (0.19) (4.36)
’24 (0.21) (0.41) (0.34) (0.18) (1.14)
’23 (0.14) (0.22) (0.13) (0.03) (0.52)
’22 (0.41) 0.09 (0.18) (0.51) (1.00)
’21 (0.17) (0.16) (0.27) (0.48) (1.08)
’20 (0.39) (0.18) (0.18) (0.04) (0.76)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 28 28 — — —
’25 23 26 26 28 103
’24 19 20 22 26 87
’23 16 16 16 18 65
’22 8 10 13 15 46
’21 5 6 6 7 24
’20 4 3 4 5 16
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 2 — — —
’25 (2) 3 2 4 7
’24 (2) (1) 2 1 0
’23 (2) (2) 1 (1) (3)
’22 (2) (1) (2) (1) (6)
’21 (1) 0 (1) (2) (5)
’20 (2) (1) (1) (1) (4)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 2 — — —
’25 (4) 1 1 4 2
’24 (2) (1) 2 1 0
’23 (2) (2) 1 (1) (4)
’22 (2) (3) 0 (1) (6)
’21 (1) 0 (2) (2) (6)
’20 (3) (1) (1) (1) (6)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 6 9 12 16 24 46 65 87 103 110 +38.5% 117 133 152 +13.9%
Gross margin, % 82.87 87.22 90.29 89.72 89.63 90.43 86.12 87.92 90.61 92.71 93.03 +9.8 pt
EBT 0 0 0 (3) (4) (8) (14) (4) (2) 0 0 (0.6%)
EBT margin, % (7.55) 5.25 2.00 (24.10) (28.52) (33.11) (30.40) (6.83) (2.24) (0.38) (0.26) +7.2 pt
Net income 0 0 0 (3) (4) (8) (8) (4) (10) (38) (32) +64.9%
Per share, $
Per share, $ Revenue 5.07 5.66 4.24 5.52 2.72 3.29 5.80 7.85 10.22 11.96 12.68 +10.0%
Earnings (0.62) 0.00 (0.25) (1.32) (0.76) (1.08) (1.00) (0.52) (1.14) (4.36) (3.71) +24.1%
Cash flow 0.38 (0.13) 0.25 (1.02) (0.70) (0.66) (0.70) (0.39) 0.00 0.79 0.66 +8.5%
Capex 0.00 (0.08) (0.01) (0.80) (0.29) (0.10) (0.09) (0.03) (0.03) (0.53) (0.14) +79.1%
Free cash flow 0.37 (0.20) 0.24 (1.82) (0.99) (0.76) (0.80) (0.42) (0.03) 0.25 0.52 (4.2%)
Book value (0.39) 0.09 0.28 3.00 1.02 4.11 5.28 5.39 4.59 0.69 0.92 n/m
Shares, m 1 1 2 2 6 7 8 8 8 9 9 +25.9%
Valuation, ×
Valuation, × P/E 0.00 26.93 37.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.4
P/S 1.08 1.06 0.71 2.92 18.36 8.99 6.99 5.22 3.25 1.95 2.50 5.1
P/B 0.00 0.00 0.00 0.00 49.00 7.20 7.68 7.60 7.24 33.96 34.59 11.3
EV/Sales 1.18 1.18 0.86 2.49 18.36 8.23 6.81 5.29 3.43 2.25 2.79 5.0
EV/FCF (1.09) (43.62) 15.39 (7.50) (50.40) (35.71) (49.54) (83.57) (348.62) 106.57 68.76 (49.8)
Cash, $m
Cash, $m Operating cash flow 0 0 1 (2) (4) (5) (6) (3) 0 7 6 +36.6%
Capex 0 0 0 (2) (2) (1) (1) 0 0 (5) (1) +125.9%
Free cash flow 0 0 0 (4) (6) (6) (6) (4) 0 2 5 +20.6%
Balance, $m
Balance, $m Working capital 1 0 1 6 1 19 8 5 18 15 20 +42.9%
Net debt 1 1 0 (5) 0 (18) (8) 5 15 29 31 +49.6%
Shareholders’ equity 0 0 1 6 6 30 42 45 39 6 8 n/m
Returns, %
Returns, % ROA (38.03) 8.76 2.25 (43.88) (41.60) (34.28) (16.29) (6.38) (11.93) (46.65) (38.13) (8.6) pt
ROIC (47.04) 8.97 32.30 (122.50) (53.64) (38.66) (23.30) (5.36) 1.46 12.92 13.49 +60.0 pt
ROE 40.41 (18.92) (0.77) 35.72 (1,007.96) (44.02) (22.09) (9.97) (23.15) (167.53) (147.79) (207.9) pt
People
People Employees 12 18 21 40 41 68 103 108 141 108 — +27.7%
Revenue/emp, $m 0.46 0.35 0.42 0.29 0.38 0.36 0.45 0.60 0.61 0.95 — +8.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Sanara MedTech Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NNNN Anbio Biotechnology $516.6M — — — — — — — Compare
ZJYL Jin Medical International Ltd. $509.4M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
ANGO AngioDynamics, Inc. $496.7M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
EMBC Embecta Corp. $358.7M 4.2× 5.3× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
SMTI Sanara MedTech Inc. $290.4M — (loss-making) 164× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33%
OSUR OraSure Technologies, Inc. $232.4M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $202.4M 21.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $195.8M 16.4× 18.8× +10.96% (above 0%: growing) −33.57% (below 0%: shrinking) +177.76% (above 0%: growing) 33.35% 17.10% Compare
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21% Compare
Median of peers $295.5M 16.4× 18.8× +2.47% −33.57% −1.40% 55.79% 17.10%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 17 April 2026

Ownership

Directors and executive officers, together 42.00%
Ronald T. Nixon 39.00%
CGI Cellerate RX, LLC 26.80%
FA Sanara, LLC 10.50%
S. Oden “Denny” Howell Jr. 5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Sanara MedTech Inc. (SMTI) Latest News

28 Oct

Impact 4 · · MarketBeat

16 Oct

Impact 4 · · Stocktwits

11 Aug

Impact 3 ·
Impact 3 ·

29 Jul

Impact 5 ·

22 Jun

Impact 3 · · Simply Wall St.

2 Jun

Impact 3 · · The Motley Fool transcript

13 May

Impact 4 · · Moby

12 May

Impact 4 · · GuruFocus.com

11 May

Impact 4 · · GlobeNewswire

5 May

Impact 4 · · Simply Wall St.

4 May

Impact 4 · · The Motley Fool transcript

23 Apr

Impact 3 · · Insider Monkey

20 Apr

Impact 4 ·

25 Mar

Impact 4 · · Moby

24 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

11 Mar

Impact 4 · · GlobeNewswire

23 Jan

Impact 4 · · GlobeNewswire

7 Jan

Impact 4 · · GlobeNewswire

6 Jan

Impact 4 · · Zacks

10 Dec

Impact 4 · · GlobeNewswire

15 Nov

Impact 3 · · Simply Wall St.MT NewswiresGuruFocus.comZacksMT NewswiresZacks

13 Nov

Impact 4 · · Simply Wall St.

12 Nov

Impact 4 · · GuruFocus.com transcript
Impact 4 · · Zacks
Impact 3 ·

11 Nov

Impact 4 · · GlobeNewswire
stockrow.com/SMTI · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com